Clinical trial

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

NCT05106335

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention camrelizumab + famitinib Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention famitinib Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2022-01-06

PhasePHASE3

Conditions

Advanced NSCLCunresolved

Interventions

camrelizumab + famitinibDRUG

famitinibDRUG

docetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

Jiangsu HengRui Medicine Co., Ltd.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05106335 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.